Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034389 | 1.00 | HSD11B1 (0.87) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1034393 | 1.00 | HSD11B1 (0.87) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1035766 | 0.93 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1771654 | 0.93 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1770864 | 0.93 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1035765 | 0.93 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL12596503 | 0.93 | HSD11B1 (0.85) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1771655 | 0.93 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1770914 | 0.92 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1770697 | 0.92 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-8399504-B2 | Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399504-B2 | Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC | 2011-05-12 | — | — | US | disclosed |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC | 2011-05-12 | — | — | US | disclosed |
| EP-2276730-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009131669-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885CYP2C9 145/4885CYP3A4 98/4885 |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885CYP2C9 92/4885CYP3A4 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.